Biostem Technologies (BSEM) M&A announcement summary

Deal rationale and strategic fit

• Acquisition of BioTissue's surgical and wound care business doubles addressable market, accelerates entry into acute wound care, and diversifies product offerings and revenue streams.

• Complements legacy business by expanding product portfolio, extending geographic reach, and enhancing market position in advanced wound healing.

• Provides access to both chronic and acute wound care markets, including hospital inpatient, outpatient, and ambulatory surgery centers, and expands access to major GPO networks.

• Integration of an experienced national sales force and commercial infrastructure accelerates commercial expansion.

• Aligns with long-term goals to build a market-leading advanced wound care business.

Financial terms and conditions

• Upfront cash payment of approximately $15 million for all purchased and licensed assets, with up to $10 million in regulatory milestone payments and up to $15 million in commercial royalty milestone payments.

• Acquired assets generated about $29 million in 2025 sales with gross margins of 65% and are expected to contribute positive EBITDA in 2026.

• Post-closing cash and equivalents balance is approximately $16 million.

Synergies and expected cost savings

• Integration of BioTissue's national sales force and GPO contracts strengthens presence in hospital and surgical settings and enhances operational efficiency.

• Manufacturing and supply agreement with BioTissue for at least 12 months, followed by in-house production expected to expand gross margins.

• Combined product suite and technology platforms anticipated to create synergies and broaden market access.